Assertio Therapeutics (ASRT) AI Stock Analysis

• Market Cap: $69.30M
• Dividend Yield: N/A
• Average Volume (3M): 295.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 9.21%
• EPS Growth: 58.12%
• Country: US
• Employees: 58
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.11
• Shares Outstanding: 96,252,090
• 10 Day Avg. Volume: 250,113
• 30 Day Avg. Volume: 295,133
• PEG Ratio: 0.04
• Price to Book (P/B): 0.69
• Price to Sales (P/S): 0.66
• P/FCF Ratio: 3.14
• Enterprise Value/Market Cap: 0.13
• Enterprise Value/Revenue: 0.07
• Enterprise Value/Gross Profit: 0.10
• Enterprise Value/Ebitda: 1.54
• 1Y Price Target: $3.00
• Price Target Upside: 310.96% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $0.79 ▲(8.49% Upside)

Assertio Therapeutics' overall stock score reflects a challenging financial performance with negative profitability and cash flow issues. While technical indicators are mixed, the earnings call provided some positive insights into sales growth and strategic initiatives. Recent corporate events are seen as positive steps towards improving the company's future prospects. However, the negative valuation metrics and ongoing challenges in profitability weigh heavily on the overall score.

Positive Factors

Revenue Growth

Sustained revenue growth indicates strong demand for Assertio's products, enhancing its market position and potential for future profitability.

Leadership Changes

The appointment of a new CEO with extensive experience is likely to bring strategic focus and drive long-term growth, benefiting shareholders and patients.

Rolvedon Sales Surge

Significant growth in Rolvedon sales reflects successful market penetration and product adoption, contributing to a stronger financial position.

Negative Factors

Profitability Challenges

Negative profit margins indicate ongoing challenges in cost management, which could hinder long-term financial stability and growth potential.

Cash Flow Management

Declining cash flow growth suggests difficulties in converting revenue into cash, potentially impacting the company's ability to invest in growth opportunities.

Indocin Sales Decline

Decreasing Indocin sales due to generic competition could weaken Assertio's revenue base, challenging its competitive position in the market.

Assertio Therapeutics Business Overview & Revenue Model

Company Description

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

How the Company Makes Money

Assertio Therapeutics generates revenue primarily through the sale of its pharmaceutical products. The company markets its approved medications through various channels, including wholesalers, pharmacies, and healthcare providers. Key revenue streams include sales from its flagship products as well as royalties and licensing fees from collaborations with other pharmaceutical companies. Additionally, Assertio may engage in partnerships or collaborations that provide upfront payments and milestone payments tied to the achievement of specific development or commercial objectives, further contributing to its earnings.

Assertio Therapeutics Financial Statement Overview

Summary

Assertio Therapeutics is experiencing a challenging financial period with mixed results across its financial statements. While revenue growth is positive, profitability remains a significant issue with negative margins. The balance sheet shows moderate leverage, but the company struggles with generating returns on equity. Cash flow management is an area of concern, with declining free cash flow growth. Overall, the company needs to focus on improving profitability and cash flow generation to enhance its financial health.

Income Statement

Assertio Therapeutics has shown a positive revenue growth rate of 17.3% in the TTM, indicating a recovery from previous declines. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains strong at 67.9%, but the negative net profit margin of -36.6% highlights ongoing challenges in managing costs and achieving profitability.

Balance Sheet

The company's debt-to-equity ratio of 0.49 in the TTM suggests a moderate level of leverage, which is an improvement from previous years. However, the return on equity remains negative, indicating that the company is not generating sufficient returns on its equity base. The equity ratio is stable, reflecting a balanced capital structure.

Cash Flow

Assertio's cash flow performance is mixed, with a decline in free cash flow growth by 26.2% in the TTM. The operating cash flow to net income ratio is low at 0.14, indicating challenges in converting earnings into cash. However, the free cash flow to net income ratio of 1.0 suggests that the company is maintaining its cash flow relative to its net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	137.35M	124.96M	152.07M	156.23M	111.01M	108.08M
Gross Profit	93.62M	85.73M	125.05M	137.49M	95.18M	92.30M
EBITDA	5.95M	5.15M	53.17M	90.17M	38.78M	-16.28M
Net Income	-28.92M	-21.58M	-331.94M	109.63M	-1.28M	-28.14M
Balance Sheet
Total Assets	319.77M	284.73M	286.42M	413.91M	326.55M	303.27M
Cash, Cash Equivalents and Short-Term Investments	93.43M	100.05M	73.44M	64.94M	36.81M	20.79M
Total Debt	39.17M	40.27M	39.68M	66.87M	75.87M	89.60M
Total Liabilities	213.97M	163.65M	148.42M	188.19M	224.13M	247.76M
Stockholders Equity	105.80M	121.08M	138.00M	225.72M	102.41M	55.51M
Cash Flow
Free Cash Flow	13.33M	26.41M	48.98M	78.32M	5.47M	-65.58M
Operating Cash Flow	13.33M	26.41M	49.60M	78.60M	5.52M	-65.57M
Investing Cash Flow	-12.57M	-48.91M	3.10M	-42.67M	-18.52M	512.80M
Financing Cash Flow	-246.00K	-350.00K	-44.20M	-7.79M	29.03M	-468.55M

Assertio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASRT, the sentiment is Negative. The current price of 0.73 is below the 20-day moving average (MA) of 0.75, below the 50-day MA of 0.78, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 43.64 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ASRT.

Assertio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPIX	55 Neutral	$65.96M	-18.66	-13.08%	―	12.21%	69.91%
ASRT	53 Neutral	$69.30M	-2.33	-24.48%	―	9.21%	58.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCYX	46 Neutral	$26.31M	-1.14	-53.29%	―	-65.77%	38.61%
RMTI	44 Neutral	$33.46M	-5.29	-16.67%	―	-23.60%	-179.33%
TLPH	41 Neutral	$51.27M	-2.83	-86.48%	―	-90.04%	44.40%
COSM	40 Underperform	$17.00M	-0.75	-63.82%	―	―	―

Assertio Therapeutics Corporate Events

Assertio Therapeutics Announces Leadership Change with CEO Resignation

On November 17, 2025, Brendan P. O’Grady, former CEO of Assertio Holdings, Inc., executed a waiver and release agreement, leading to his resignation from the company’s Board of Directors. This move marks a significant leadership change within the company, potentially impacting its strategic direction and stakeholder interests.

Assertio Therapeutics Promotes Paul Schwichtenberg to President

On November 10, 2025, Assertio Holdings, Inc. announced its financial results for the third quarter of 2025, highlighting a significant increase in Rolvedon net product sales, which rose to $38.6 million from $15.0 million in the prior-year quarter. This growth was attributed to both normal demand and large purchases by national distributors. The company also promoted Paul Schwichtenberg to the role of President and Chief Operating Officer, effective November 3, 2025, as part of its strategic efforts to consolidate operations and enhance commercial strategies. Assertio narrowed its full-year 2025 net product sales guidance range to $110 to $112 million and adjusted EBITDA range to $14 to $16 million, reflecting the impact of the Rolvedon pull-forward.

Assertio Therapeutics Announces New CEO Appointment

On October 27, 2025, Assertio Holdings announced the departure of CEO Brendan O’Grady and the appointment of Mark Reisenauer as the new CEO. This leadership transition aims to accelerate growth and enhance efficiency as the company enters 2026, with Reisenauer bringing extensive experience in oncology and specialty spaces to drive long-term value for shareholders and patients.

Assertio Therapeutics Amends ROLVEDON Supply Agreement

On October 7, 2025, Spectrum Pharmaceuticals, a subsidiary of Assertio Holdings, and Hanmi Pharmaceutical amended their supply agreement for ROLVEDON drug substance, establishing long-term pricing with a mid-single digit percentage reduction. The amendment allows for price adjustments based on market volume and cost increases, requiring Spectrum’s consent for manufacturing changes, and mandates an annual forecasted purchase plan without minimum purchase requirements.